Microbiota-associated alterations in BA homeostasis and farnesoid X receptor signaling, via FGF19, might thus contribute to fibrogenesis, liver injury, and tumorigenesis in NASH-HCC. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.